Hafnium oxide
- Generic Name
- Hafnium oxide
- Drug Type
- Small Molecule
- Chemical Formula
- HfO2
- CAS Number
- 12055-23-1
- Unique Ingredient Identifier
- 3C4Z4KG52T
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Phase 2
Recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT06667908
- Locations
- 🇺🇸
University of Vermont Medical Center, Burlington, Vermont, United States
🇺🇸University of Connecticut Health Center, Farmington, Connecticut, United States
🇺🇸Orlando Health Cancer Institute, Orlando, Florida, United States
NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy
Phase 1
Recruiting
- Conditions
- RadiotherapyImmunotherapyMicrosatellite Instability-High Solid Malignant TumourMetastasis from Malignant Tumor of LiverSquamous Cell Carcinoma of Head and NeckMetastasis from Malignant Tumor of CervixMetastasis from Malignant Melanoma of Skin (disorder)Metastatic Triple-Negative Breast CarcinomaMetastatic NSCLCMetastatic Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2018-07-17
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Nanobiotix
- Target Recruit Count
- 145
- Registration Number
- NCT03589339
- Locations
- 🇺🇸
Christus St. Vincent Regional Cancer Center, Santa Fe, New Mexico, United States
🇺🇸St Luke's University Health Network, Bethlehem, Pennsylvania, United States
🇺🇸Sanford Cancer Center, Sioux Falls, South Dakota, United States
A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer
Phase 1
Terminated
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- PharmaEngine
- Target Recruit Count
- 12
- Registration Number
- NCT02901483
- Locations
- 🇨🇳
Keelung Chang Gung Memorial Hospital (Lovers Lake Branch), Keelung, Taiwan
A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Rectal Cancer
Phase 1
Terminated
- Conditions
- Rectal Cancer
- Interventions
- Procedure: surgical resectionRadiation: Radiotherapy
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- PharmaEngine
- Target Recruit Count
- 32
- Registration Number
- NCT02465593
- Locations
- 🇨🇳
Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath